Have you been newly diagnosed with early-stage invasive breast cancer?

Vilma M.
Speech-language pathologist and mother of 2.
Diagnosed with invasive breast cancer at age 48.
“The additional information provided by the Oncotype DX® test made a difficult decision much easier. I felt as if I had made the best possible decision for me, and I was able to concentrate all my energies on getting better.”

-Sandy P., mother and teacher. Diagnosed with invasive breast cancer at 38.
Have you recently been diagnosed with early-stage invasive breast cancer? Are you struggling to make treatment decisions? If so, you may be interested to know that not all women with early-stage breast cancer benefit from chemotherapy. Oncotype DX test helps identify which women with early-stage, estrogen receptor-positive (ER+) invasive breast cancer are more likely to benefit from adding chemotherapy to their hormonal treatment.

Planning Your Treatment

After a breast cancer diagnosis, doctors and patients work together to plan an appropriate course of treatment. The first step is usually surgery to remove the tumor. Following surgery, the next step is to determine how likely your cancer is to return, which may help you and your doctor make decisions about future treatment options, and whether or not to include chemotherapy.
It is overwhelming to receive a diagnosis of breast cancer. It is important to gather as much information as possible to determine a treatment plan that is right for you. Your doctor may consider many factors in planning your treatment, including:

- your age and medical history
- the size and grade of your tumor
- whether your tumor has spread
- whether there are estrogen receptors and HER2 receptors on the cells of your tumor
- your treatment preferences
- the results of your Oncotype DX test

Because every patient’s breast cancer is unique, understanding the tumor biology will help you and your doctor personalize your treatment plan.
What Is the Oncotype DX Test?

The Oncotype DX test is a unique diagnostic test that measures a group of cancer-related genes in your breast tumor tissue. The test gives you a Recurrence Score® result, which provides information regarding:

• the chances of your breast cancer returning
• the likelihood that chemotherapy will or will not help you

Why Should I Consider this Test?

This test provides information specific to your tumor, not available from traditional factors. Since the test provides individualized information, it enables the treatment plan to be tailored specifically for you. Speak with your healthcare team to understand how the Oncotype DX result may impact your treatment planning.

Is the Test Right for Me?

You may be a candidate for the Oncotype DX test if you are newly diagnosed with early stage-invasive breast cancer that is both:

• Hormone (estrogen or progesterone) receptor-positive (ER+ or PR+)
• HER2-negative
How Is the Oncotype DX Test Performed?

The test is performed on a small amount of your tumor tissue that was removed during your original surgery (lumpectomy, mastectomy, or core biopsy). This tissue is routinely saved and stored at the hospital where you had your surgery.

You will NOT have to go through any additional surgery or procedure to get the Oncotype DX test.

When Should the Test Be Done?

It is important that your doctor request the Oncotype DX test before you start any treatment, since the test is intended to help determine how likely your cancer is to return, which may guide treatment decisions.
“Before my Oncotype DX test, the people at Genomic Health called to tell me that they had taken care of the insurance paperwork for me so I wouldn’t have to worry about that. Three days later, I heard from Genomic Health that my insurance would cover the cost of the test, long before I ever heard back from the insurance company itself. It was quite a relief, given all of the other stress.”

Deborah W., professional painter.
Diagnosed with invasive breast cancer at age 53.
How Do I Get the Oncotype DX Test?

The test can only be ordered by a licensed healthcare professional, such as your doctor. You may wish to talk with your healthcare team and ask if the Oncotype DX test may be of benefit to you.

How Long Will It Take to Get the Results?

Most results from the Oncotype DX test are available within 7 to 14 days from the date the tumor sample is received by the Genomic Health® laboratory. The results are sent to your doctor so that he or she can discuss the results with you and answer your questions.

Is the Test Covered by Insurance?

The Oncotype DX test is covered by Medicare and by most private insurance companies.

In addition, Genomic Health offers the Genomic Access Program (GAP), a comprehensive program designed to help you with the coverage process and provide financial assistance when necessary, based on eligibility. Please call (866) ONCOTYPE (866-662-6897) for more information on insurance and for financial-aid questions.
Understanding Your Recurrence Score Result

Your doctor will receive a report with the results of your Oncotype DX test that contains your Recurrence Score result:

DISTRIBUTION OF RECURRENCE SCORE RESULTS (0-100)

A lower Recurrence Score result means:
• Your cancer is less likely to come back in 10 years
• Chemotherapy is less likely to benefit you

A higher Recurrence Score result means:
• Your cancer is more likely to come back in 10 years
• Chemotherapy is more likely to benefit you

It is important to understand that a lower Recurrence Score result does not mean that there is no chance that your breast cancer will return. Also, a higher Recurrence Score result does not mean that your breast cancer will definitely return.

The results also provide additional information, such as the activity levels of the estrogen and progesterone receptors in your tumor, which may also help guide your treatment.
For insurance, financial aid, or other questions about the Oncotype DX test, please call US (English) **866-ONCOTYPE** (866-662-6897), US (Spanish) **877-444-9876**, and international **001-650-569-2080**.

**For more information about this and other Oncotype DX tests, please visit genomichealth.com or oncotypedx.com.**

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Such matters should be discussed with your healthcare provider.

The people shown in this booklet used the Oncotype DX breast cancer test in making their treatment decisions with their physicians.

Learn more about the patient stories at MyBreastCancerTreatment.org